For most of history, patients have been the passive recipients of medical care with little or no role in research. Even as research subjects, patients were not required to give informed consent prior to adoption of the Nuremburg Code in 1947. Since then, patient participation has expanded dramatically, and today, opportunities abound to serve as active partners in def ning and prioritizing research questions and solutions. As digital strategist Leonard Kish declared in 2012, "If patient engagement were a drug, it would be the blockbuster drug of the century and malpractice not to use it" (1) .
Patient engagement offers the promise of advancing more personal and eff cacious medical products faster than the typical ~15-year discovery-to-market timeline (2) . Here, we explore the early foundations of patient engagement (table S1) , where it occurs in the drug-development pipeline, the power of recent policy initiatives, and prospects for success in improving health outcomes.
FROM SIDELINES TO CENTER COURT
Early in the last century, patients began to mobilize to accelerate research for particular conditions. T e March of Dimes, founded by President Franklin D. Roosevelt in 1938 to expand polio research, is one of the f rst examples of philanthropy directed at f nding treatments and cures. Research supported by individuals through the March of Dimes led to development of the "iron lung" and a successful vaccine. Until recently, this case was an outlier, considering that until the 1973 Patient Bill of Rights was adopted by the American Hospital Association, patients did not necessarily expect to be told their diagnosis, much less have a voice in determining their care plan.
Even in recent years, patients didn't always express their own preferences and expectations for care, deferring to choices the doctor deemed best.
T e HIV/AIDS movement catapulted patient needs to the forefront of research and created the force for change that dramatically altered regulatory approval processes at the U.S. Food and Drug Administration (FDA), funding formulas and emphasis at the U.S. 
POLICY PROSPECTS CONVERGE
T e past year has ushered in a "perfect storm" of policy initiatives in biomedical research and opportunities for patient engagement. In April 2014, the chairman of the U.S. House of Representatives Energy and Commerce Committee, Fred Upton, partnered with Rep. Diana DeGette to launch the 21st Century Cures Initiative with a series of hearings and roundtable discussions around the country. T ese listening sessions solicited unprecedented public input about how Congress could help "accelerate the discovery, development, and delivery of promising new therapies and cures for patients and maintain our nation's standing as the biomedical-innovation capital of the world" (4). In recognition of the committee's patient-centered emphasis, Title 1 of the f rst draf of proposals-released on 27 January 2015-was titled "Putting patients f rst by incorporating their perspectives into the regulatory process and addressing unmet medical needs" (5) . T e proposals also include patient representatives in nearly every council, panel, advisory board, and body that would be created under the act.
Two days later, a companion ef ort was announced in the U.S. Senate under the Health, Education, Labor, and Pensions Committee entitled "Innovation for healthier Americans: Identifying opportunities for meaningful reform to our nation's medical product discovery and development" (6) . It highlighted disease registries sponsored by nonprof t organizations as a "way for patients with a specif c disease to signal their potential willingness to participate in research on that disease" and public-private partnerships as a means to "bring academia, government, patients, industry, and others together to solve complex scientif c and process questions about medical product development. "
T e next day, the executive branch added its voice to the chorus when U.S. President Barack Obama announced the Precision Medicine Initiative, a "moon shot" type project that includes the building of a cohort of 1 million engaged participants to contribute data and insights over many years, enabling researchers to better understand how genomic variations and other health factors af ect disease development. T e president's invitation outlined a collaborative approach to identifying superior treatments and prevention strategies: "In order for us to realize [the Initiative's] potential, I'm asking more hospitals and researchers and privacy experts to join us in this ef ort. I'm asking entrepreneurs and nonprof ts to help us create tools that give patients the chance to get involved as well. Because we want every American ultimately to be able to securely access and analyze their own health data, so that they can make the best decisions for themselves and for their families. "
Negotiations for the sixth authorization of PDUFA will begin this fall among the FDA, Congress, and the biopharmaceutical industry. For the second time, patient representatives will have an active role in the process, although not quite full negotiating status, because user fees are paid by industry to FDA with oversight from Congress. Most recognize that patients' inf uence and the open dialogue among stakeholders under the 21st Century Cures initiative has served as a dress rehearsal-in particular, these new actors are given opportunities to contribute to the hashing out of ideas, alignment of goals, and vetting of approaches to meeting those goals.
For example, FasterCures, the Biotechnology Industry Organization, and Eli Lilly & Co. developed independent yet complementary proposals for Congress as part of 21st Century Cures to authorize a publicprivate partnership dedicated to developing tools and methods to support science-based approaches for collecting patient input. T e bipartisan discussion draf includes such a body, the "Council for 21st Century Cures, " whose mandate is to "accelerate the discovery, development, and delivery in the United States of innovative cures, treatments, and preventive measures for patients" (7).
THE SCIENCE OF PATIENT INPUT
Accompanying acceptance of the need to integrate patient perspectives is an increase in the demand for research-based methods and tools to measure the ef ectiveness of incorporating patient input into the system and, ultimately, its impact on patient health. What began as an extension of patient advocacy has evolved into an emerging scientif c discipline aimed at understanding and incorporating patient needs into the processes of developing, regulating, and delivering new therapies.
A compelling "call to action" authored by thought leaders from international patient organizations and pharmaceutical companies describes the gap that must be closed: "Despite the increasing number and scope of patient-involvement initiatives, there is no accepted master framework for systematic patient involvement in industryled medicines research and development, regulatory review, or market access decisions.… It is essential that all stakeholders participate to drive adoption and implementation of the framework and to ensure that patients and their needs are embedded at the heart of medicines development and lifecycle management" (8) . Meetings convened in the f rst quarter of 2015 by the Clinical Trials Transformation Initiative, National Health Council, University of Maryland's Center of Excellence for Regulatory Science Innovation, and PCORI have provided opportunities to share emerging practices and lessons learned.
For medical devices and biologics, the call to action was answered by the FDA's CDRH and Center for Biologics Evaluation and Research on 13 May 2015, with a draf guidance entitled "Patient preference information-Submission, review in PMAs, HDE applications, and de novo requests, and inclusion in device labeling" (9) . T e guidance outlines "qualities" of patientpreference information acceptable for regulatory purposes and directions for submitting such data to the agency. On the same date, the Medical Device Innovation Consortium (MDIC), a public-private partnership, released its "Framework and catalog of methods for incorporating information on patient preferences regarding benef t and risk into the regulatory assessments of new medical technologies" (10) . T e catalog captures methods of assessing patient preference that are adapted from health economics, outcomes research, epidemiology, social sciences, and marketing sciences. Although compiled for medical technology development, the catalog is expected to be highly transferable to the development of pharmaceuticals and biologics as well.
FOCUS
For drugs, the groundwork has been laid by researchers who participated in early organized ef orts to develop structured assessment of benef ts and risks, including the Benef t-Risk Assessment Team convened by the Pharmaceutical Research and Manufacturers of America, the Centre for Innovation in Regulatory Sciences, and special interest groups within the International Society for Pharmacoeconomics and Outcomes Research. FasterCures's Benef t-Risk Advisory Council comprises many of these experts along with patient leaders and provided the faculty for a one-day "benef t-risk boot camp" on this topic in September 2014.
On a parallel track, patient organizations have piloted new approaches to meet the demand for data that supplement personal testimony and participation of individual advocates as patient representatives in decision-making bodies. Parent Project Muscular Dystrophy (PPMD) demonstrated leadership in sponsoring a benef t-riskpreference study among parents of boys with the rare but fatal form of muscular dystrophy known as Duchenne. PPMD published the results, held a policy forum that attracted 17 FDA of cials, and organized a community-based draf ing of a regulatory guidance for drug development. T e FDA opened a public docket to receive comments on PPMD's guidance document and is expected to issue its version in coming weeks. Other patient organizations are following PPMD's model-seeking academic partners, building patient registries, and educating their patient communities about new opportunities to reshape treatment pipelines and care delivery.
ACCOUNTABILITY ALL AROUND
To fulf ll the prediction that patient engagement will be the blockbuster drug of the century, we of er f ve observations to guide the path forward:
• T ere is a need to expand the capacity of all participants-industry, academia, government, and patient organizations-to engage patients in biomedical research, medical product development, regulatory decisionmaking, and health care delivery. We must understand the full range of patient experiences and expectations across a representative cross section of individuals with a particular diagnosis or collection of conditions.
• Developing appropriate, scalable, sustainable methods and practices will require collaboration, experimentation, coordination, and transparency. Multiple types of expertise will be needed, and adoption will be highly iterative and require extreme focus on the goal: improved patient outcomes.
• It's too early to tout emerging practices as being "best, " and standards are likely to change rapidly. T is may challenge resources and introduce new sources of uncertainty, especially at f rst. We may all need to tolerate more turbulence in the ascent, with our seatbelts fastened, before we reach a comfortable cruising altitude.
• Dif erent diseases, disease communities, stages of disease, and stages of life might warrant distinct approaches to patient engagement and integration of patient input. T e role of the caregiver and family members is clear in pediatric disorders, disabilities, and conditions associated with aging such as Alzheimer's disease; individuals who surround the patients also should be factored into our understanding of unmet medical needs in mental-health conditions such as addiction and schizophrenia.
• Patients are found not only in conventional settings, such as disease-specif c foundations and clinics, but also living their lives as members of social media networks and local community organizations. We need to rethink and expand the settings in which we recruit and equip individuals to be informed participants in research and care activities. T is will take time to implement.
Medical products and interventions that begin with a solid understanding of patient needs and expectations promise better outcomes for the individual, families, communities, our nation, and global health. More than 75 years ago, patient engagement contributed to arresting the polio epidemic. T e HIV/AIDS activists charted a path forward for the way patients can engage in all aspects of research and delivery of care under stunningly dif cult circumstances. With advances in the tools we have for conducting science and communication, think of the potential we have to capitalize on the blockbuster that is patient engagement. T e possibilities are endless.
SUPPLEMENTARY MATERIALS
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